Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications
By
- AMS
posted
Sep 10, 2020 07:51 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma
- AMS
Added Oct 23, 2020
Blog Entry
Development and validation of a prognostic nomogram model in primary cutaneous and subcutaneous soft tissue angiosarcoma
- AMS
Added Aug 25, 2021
Blog Entry
Elderly patients with psoriasis: long-term efficacy and safety of modern treatments
- AMS
Added Aug 20, 2020
Blog Entry
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population
- AMS
Added Feb 16, 2021
Blog Entry
Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study
- AMS
Added Jul 23, 2020
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic